Literature DB >> 26634589

ALLERGIC RHINITIS AND ADENOID HYPERTROPHY IN CHILDREN: IS ADENOIDECTOMY ALWAYS REALLY USEFUL?

L Colavita1, M Miraglia Del Giudice2, G Stroscio3, C Visalli3, T Alterio4, C Pidone4, M R Pizzino4, T Arrigo4, R Chimenz5, C Salpietro4, C Cuppari4.   

Abstract

Allergic rhinitis (AR) and adenoid hypertrophy (AH) are common in children and are often associated with each other. Recent studies have shown improvement of respiratory symptoms and reduction in the adenoid volume after anti-allergic medical therapy (intranasal corticosteroids, antihistamines). The aim of our retrospective study is to evaluate the effectiveness of adenoidectomy on respiratory symptoms in pediatric patients with AR. We recruited 404 pediatric patients with AR, and we divided them into 4 groups (1. intermittent-mild rhinitis; 2. intermittent-moderate/severe rhinitis; 3. persistent-mild rhinitis; 4. persistent-moderate/severe rhinitis), using ARIA classification. For each patient we evaluated: age at onset of AR; family history of allergy; the presence of other allergic diseases; serum total IgE values; skin prick test (SPT) results; presence of AH evaluated by rhino-laringeal fibroscopy; adenoidectomy and its efficacy on respiratory symptoms. Our data show an association between AR and AH: 90 of 404 (22%) children with AR had AH of a degree greater than 2nd. A significant percentage (80%) of children suffering from AR did not present satisfactory benefits from adenoidectomy. They reported persistence or recurrence of rhinitic symptoms after surgery or only partial benefits, especially of recurrent respiratory tract infections and nasal obstruction. The local allergic persistent inflammation on nasal mucosa and adenoid tissue is probably the cause of the unsatisfactory results of adenoidectomy, therefore surgery cannot be the first therapeutic step for these children. It is important to extinguish the local inflammation by medical anti-allergic therapy to obtain improvements of nasal symptoms and to prevent adenoid regrowth.

Entities:  

Year:  2015        PMID: 26634589

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  7 in total

1.  Assessment of the causes of second surgery following pediatric adenotonsillar surgery.

Authors:  Zhengcai Lou; Zi-Han Lou
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-21       Impact factor: 2.503

2.  Adenoid hypertrophy in children and allergic rhinitis.

Authors:  Zhengcai Lou
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-08       Impact factor: 2.503

3.  Skin Prick Test Analysis in Allergic Rhinitis Patients: A Preliminary Study in Abuja, Nigeria.

Authors:  P U Ibekwe; T S Ibekwe
Journal:  J Allergy (Cairo)       Date:  2016-05-10

4.  The Impact of the Thermal Seasons on Adenoid Size, Its Mucus Coverage and Otitis Media with Effusion: A Cohort Study.

Authors:  Krystyna Masna; Aleksander Zwierz; Krzysztof Domagalski; Paweł Burduk
Journal:  J Clin Med       Date:  2021-11-28       Impact factor: 4.241

5.  Update of endoscopic classification system of adenoid hypertrophy based on clinical experience on 7621 children.

Authors:  Michele Cassano; Eugenio De Corso; Valeria Fiore; Rossana Giancaspro; Antonio Moffa; Manuele Casale; Eleonora Maria Consiglia Trecca; Dario Antonio Mele; Pasquale Cassano; Matteo Gelardi
Journal:  Acta Otorhinolaryngol Ital       Date:  2022-04-08       Impact factor: 2.618

6.  Detecting epidemiological relevance of adenoid hypertrophy, rhinosinusitis, and allergic rhinitis through an Internet search.

Authors:  Yingchao Yang; Xinyi Li; Qiang Ma; Zhihui Fu; Kaiming Su
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-09       Impact factor: 3.236

7.  The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model.

Authors:  Han Xiao; Jinqiang Huang; Weifeng Liu; Zihao Dai; Sui Peng; Zhenwei Peng; Ruiming Liang; Renqiang Ma; Yihui Wen; Jian Li; Weiping Wen
Journal:  Qual Life Res       Date:  2019-11-28       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.